159 related articles for article (PubMed ID: 37361578)
1. Ribociclib in newly diagnosed hepatitis B infection: A case report.
Di Costanzo F; Carrano S; Iengo G; Cefaliello A; Cossiga V; Morisco F; Giuliano M; De Angelis C; Arpino G
Front Oncol; 2023; 13():1184952. PubMed ID: 37361578
[TBL] [Abstract][Full Text] [Related]
2. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.
Topcu A; Yasin AI; Shbair AT; Besiroglu M; Simsek M; Sucuoglu Z; Yurtsever I; Gucin Z; Seker M; Turk HM
J Oncol Pharm Pract; 2022 Jan; 28(1):242-246. PubMed ID: 34162247
[TBL] [Abstract][Full Text] [Related]
3. Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab.
Bayram D; Aktürk Esen S; Uçar G; Köş FT
J Oncol Pharm Pract; 2023 Sep; 29(6):1494-1497. PubMed ID: 37170613
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib-induced pulmonary infiltrates in a patient with breast cancer.
Ünsal O; Özet A
J Oncol Pharm Pract; 2023 Sep; 29(6):1537-1540. PubMed ID: 37524106
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib-induced liver injury: a case report.
Schaeffer S; Lutz C; Dobbie M; Terracciano LM; Matter M; Vosbeck J; Heim MH; Bernsmeier C
Front Oncol; 2023; 13():1256783. PubMed ID: 38107071
[TBL] [Abstract][Full Text] [Related]
6. Ribociclib-induced hepatotoxicity.
Er MM; Araz M; Hendem E; Eryılmaz MK; Artaç M
J Oncol Pharm Pract; 2023 Jul; 29(5):1275-1277. PubMed ID: 36762416
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.
Schettini F; Seguí E; Conte B; Sanfeliu E; Gonzalez-Farre B; Jares P; Vidal-Sicart S; Ganau S; Cebrecos I; Brasó-Maristany F; Muñoz M; Prat A; Vidal M
Front Oncol; 2022; 12():1009352. PubMed ID: 36425558
[TBL] [Abstract][Full Text] [Related]
8. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.
Abdel-Razeq H; Sharaf B; AlMasri R; Abdel-Razeq R; Tamimi F; Khader O; Salama O; Abunasser M; Edaily S; Abdulelah H
Cancer Manag Res; 2022; 14():1033-1041. PubMed ID: 35300061
[TBL] [Abstract][Full Text] [Related]
10. Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib.
Watts C; Nadori K
J Oncol Pharm Pract; 2023 Jun; 29(4):962-966. PubMed ID: 36000297
[TBL] [Abstract][Full Text] [Related]
11. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer.
Türkel A; Karaçin C; Öner İ; Şeyran E; Öksüzoğlu B
J Oncol Pharm Pract; 2023 Feb; ():10781552231156521. PubMed ID: 36760158
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
13. Vortex keratopathy associated with ribociclib.
Türkel A; Özdoğan S; Yekedüz E; Şeyran E; Karaçin C; Ateş Ö
J Oncol Pharm Pract; 2023 Jan; 29(1):230-232. PubMed ID: 35570741
[TBL] [Abstract][Full Text] [Related]
14. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
15. Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
Rudlowski C; Beermann N; Leitzen L; Nuding B
Breast Care (Basel); 2020 Jun; 15(3):289-293. PubMed ID: 32774224
[TBL] [Abstract][Full Text] [Related]
16. Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review.
Stanciu IM; Pirlog CF; Anghel AW; Parosanu AI; Olaru CM; Orlov-Slavu C; Iaciu IC; Popa AM; Vrabie RC; Nitipir C
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109654
[TBL] [Abstract][Full Text] [Related]
17. The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
Botticelli A; Fabbri A; Roberto M; Alesini D; Cirillo A; D'Auria G; Krasniqi E; Marrucci E; Muratore M; Pantano F; Pizzuti L; Portarena I; Rossi R; Scagnoli S; Marchetti P
Front Oncol; 2022; 12():797157. PubMed ID: 35223478
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
19. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
[TBL] [Abstract][Full Text] [Related]
20. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
Giuliani J; Bonetti A
J Oncol Pharm Pract; 2020 Sep; 26(6):1486-1491. PubMed ID: 32576084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]